Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

NCT03448718 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG: Olaparib

Sponsor

Matthew Galsky

Collaborators

[object Object]
[object Object]